GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Kura Oncology Inc.
Kura Oncology is a biotech company focused on developing targeted drugs for the treatment of blood cancers. Its stock price is driven by news from clinical trials. The chart reflects investor confidence in the potential of its precision medicine to combat leukemia.
Share prices of companies in the market segment - Cancer blood
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers such as leukemia. We've classified it in the "Blood Cancer" segment, and the chart below shows how investors view the prospects of companies in this complex area of oncology.
Broad Market Index - GURU.Markets
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers such as leukemia. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
KURA - Daily change in the company's share price Kura Oncology Inc.
Shares of Kura Oncology, a developer of targeted cancer therapies, are exhibiting the extreme volatility typical of biotech. change_co tracks investor reactions to the release of clinical trial data. This metric is key to building valuation models for high-risk pharmaceutical assets on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer blood
Kura Oncology, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with KURA's performance, which depends on clinical trial results, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Kura is a biopharmaceutical company developing drugs to treat blood cancers. Oncology, particularly hematology, is a highly volatile sector. The chart below reflects the average fluctuations in this industry, providing context for assessing the risks and potential of Kura shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Kura Oncology Inc.
Kura is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Annual dynamics of market capitalization of the market segment - Cancer blood
Kura Oncology, Inc. is a clinical-stage biotech developing targeted therapies for the treatment of blood cancer. Its stock performance is driven entirely by clinical trial results and partnerships, not revenue. This chart shows how the market views the company's scientific potential and risks compared to the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kura Oncology is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Kura Oncology Inc.
ADTRAN, a provider of telecommunications equipment for access network construction. The monthly fluctuations on the chart reflect the capital expenditure cycles of telecom operators investing in expanding fiber-optic and wireless networks.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers. This segment of oncology is one of the fastest-growing but also highly competitive. The chart below shows how investors assessed the prospects of companies working on targeted therapies for cancer.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kura Oncology is a clinical-stage biotech company focused on treating blood cancer. Its shares are a classic venture bet on the success of scientific developments. Their price can fluctuate sharply following the publication of clinical trial news, completely ignoring overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Kura Oncology Inc.
Kura Oncology is a biotech company focused on blood cancer treatment. Its weekly stock price is highly volatile and depends on news about clinical trials of its targeted drugs, as is typical for this sector.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Kura Oncology is a biotech company focused on cancer treatment. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart shows how news about clinical trials of its targeted drugs drives share price movements independent of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Kura, a biotech company, exist in a world of their own, far removed from macroeconomic news. Their performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can move regardless of the broader market.
Market capitalization of the company, segment and market as a whole
KURA - Market capitalization of the company Kura Oncology Inc.
Kura Oncology's market capitalization chart tells the story of precision drug development for cancer treatment. The company focuses on targeted therapies that target specific genetic drivers of tumors. Its volatile chart reflects the hopes and risks associated with clinical trials of drugs that could change the treatment paradigm.
KURA - Share of the company's market capitalization Kura Oncology Inc. within the market segment - Cancer blood
Kura Oncology is a clinical-stage biotechnology company developing precision-targeted therapies for the treatment of cancer, particularly leukemia. Its market share reflects the potential of its leading developments. The chart below shows the market weighting of its chances of success in the fight against blood cancer.
Market capitalization of the market segment - Cancer blood
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. The chart below shows the overall market capitalization of the oncology sector. It illustrates the potential of targeted therapies targeting specific genetic drivers of cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Kura Oncology pipeline on this chart represents a precision attack on cancer. The company develops drugs that target specific genetic drivers of blood and solid tumors. Its volatile market cap reflects progress in clinical trials. This is a visualization of the future of personalized oncology.
Book value capitalization of the company, segment and market as a whole
KURA - Book value capitalization of the company Kura Oncology Inc.
Kura Oncology's book value is derived from its financial reserves and intellectual property for targeted therapy drugs for blood cancer. This represents focused scientific capital. The chart shows how the biotech company manages its research budget as it develops a new generation of leukemia drugs.
KURA - Share of the company's book capitalization Kura Oncology Inc. within the market segment - Cancer blood
Kura Oncology is a biotech company developing targeted drugs for the treatment of blood cancer. Its assets include laboratories and intellectual property. The chart shows a minimal share of physical assets, as the company is focused on research and clinical trials.
Market segment balance sheet capitalization - Cancer blood
Developing targeted therapies like Kura Oncology's is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its patents. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Kura Oncology's book value is not its product lines, but rather its capital and intellectual property, which are used to conduct clinical trials of targeted drugs for the treatment of blood cancers and solid tumors. These assets reflect the financial resources available for developing targeted therapies for oncology. The chart illustrates the scale of this biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Kura Oncology Inc.
For Kura Oncology, which develops targeted cancer drugs, market capitalization is a bet on the success of its research. Its ratio to book value (its cash) reflects the degree of investor confidence in its scientific approach and the potential of its drugs.
Market to book capitalization ratio in a market segment - Cancer blood
Kura Oncology is a biotech company focused on targeted therapies for blood cancer. Its high valuation on this chart reflects investor hopes that its drugs will become a new standard of care for certain patient groups.
Market to book capitalization ratio for the market as a whole
Kura Oncology is a clinical-stage biotechnology company focused on developing precision drugs for the treatment of cancer, particularly leukemia. Its valuation is based on the success of its targeted therapies in clinical trials. This metric reflects how investors value companies working on personalized medicine in oncology.
Debts of the company, segment and market as a whole
KURA - Company debts Kura Oncology Inc.
Kura Oncology, a biotech company focused on treating blood cancer, is raising capital, including debt, to fund its clinical trials. For a company at the forefront of science, access to funding is key to survival and potential success. This chart shows the cost of innovation in oncology.
Market segment debts - Cancer blood
Kura Oncology is a clinical-stage biotech company focused on developing targeted therapies for cancer, particularly blood cancer. This chart shows how the company is raising capital from investors to fund its expensive and lengthy clinical trials, a typical model for biopharmaceutical startups without commercial revenue.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Kura Oncology Inc.
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. The path from idea to approved drug is long, expensive, and fraught with risks. This chart illustrates how heavily the company relies on debt to finance its advanced, but not yet profitable, clinical programs.
Market segment debt to market segment book capitalization - Cancer blood
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers. Oncology is one of the most expensive areas of research. This chart shows how the company finances its clinical trials, comparing its debt structure to the overall financial picture in the biotech sector.
Debt to book value of all companies in the market
Kura Oncology is a biopharmaceutical company focused on treating blood cancers. Oncology drug development is a long and expensive process. How heavily does Kura Oncology rely on debt to fund its clinical trials? This chart of total market debt provides investors with context for assessing its financial strength.
P/E of the company, segment and market as a whole
P/E - Kura Oncology Inc.
Kura Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. This chart shows how investors view its scientific approach. This valuation is heavily dependent on clinical trial results and the potential of its drugs.
P/E of the market segment - Cancer blood
Kura Oncology is a clinical-stage biotech company specializing in the development of targeted therapies for the treatment of blood cancers and solid tumors. This chart shows the average valuation for the sector, providing investors with context for assessing the company's scientific pipeline and the risks associated with oncology drug development.
P/E of the market as a whole
Kura Oncology is a clinical-stage biopharmaceutical company developing targeted therapies for blood cancer. Valuing such companies is a bet on the success of clinical trials. Does comparing this chart reveal the extent to which Kura investors are ignoring the broader market picture, betting solely on its scientific potential and research data?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Kura Oncology Inc.
Kura Oncology is a biopharmaceutical company developing targeted therapies for the treatment of blood cancers and solid tumors. It focuses on precision medicine. This chart shows market expectations for the success of its clinical programs. Future revenue depends on regulatory approvals and the commercial potential of its innovative drugs.
%20P%2FE%20Kura%20Oncology%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kura-Oncology-Inc.&v=1772650217510 "Chart of the company's future (projected) P/E Kura Oncology Inc.")
Future (projected) P/E of the market segment - Cancer blood
Kura Oncology is a biopharmaceutical company developing targeted therapies for the treatment of blood cancers and solid tumors. Its approach is based on precision medicine. The chart shows forecasts for the oncology sector. This allows for a comparison of how the market views Kura's scientific platform and the potential of its leading drug candidates compared to competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772650217544 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Kura Oncology, Inc. is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers. Its valuation depends on the success of its clinical programs. This overall risk appetite chart shows how willing investors are to support science-based companies working on personalized cancer treatments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772650217587 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Kura Oncology Inc.
Kura Oncology is a biopharmaceutical company developing targeted drugs for the treatment of blood cancers. While in the clinical stage, it has no commercial products, and its financial performance reflects R&D expenses. This chart shows the cost of innovation in oncology, where losses today can save lives tomorrow.
Profit of companies in the market segment - Cancer blood
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. This chart, showing the profitability of the oncology sector, reflects the enormous investment in the fight against cancer. Kura's success depends on the clinical data of its drugs, and the overall health of the sector ensures an influx of capital into this vital research.
Overall market profit
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers. This is one of the fastest-growing areas in oncology. Kura's success depends on scientific breakthroughs and investment. This graph of overall market returns shows how willing investors are to fund cutting-edge, yet risky, biotech developments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Kura Oncology Inc.
Kura Oncology is a biopharmaceutical company developing targeted therapies for the treatment of blood cancers and solid tumors with specific genetic mutations. Its future depends on the success of clinical trials. This chart summarizes analyst opinions on the potential of their leading candidates and the likelihood of their market entry.
%20profit%20of%20the%20company%20Kura%20Oncology%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kura-Oncology-Inc.&v=1772650217636 "Graph of future (projected) profit of the company Kura Oncology Inc.")
Future (predicted) profit of companies in the market segment - Cancer blood
Kura Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. Its future depends on the success of clinical trials. This chart for the oncology sector reflects the general investor confidence that precision medicine will lead to new breakthroughs in cancer treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772650217648 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Kura Oncology is a biopharmaceutical company focused on the treatment of blood cancers. Its primary driver is successful clinical trials. However, the overall economic environment reflected in this forecast impacts the availability of capital and strategic decisions of large pharmaceutical companies that may be potential partners for Kura.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772650217654 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Kura Oncology Inc.
Kura Oncology is a biotech company focused on developing targeted therapies for the treatment of blood cancers. Since the company is in the clinical stage, this chart is key. It demonstrates the enormous value investors place on the future sales of its innovative drugs, betting on breakthroughs in the treatment of difficult-to-treat diseases.
P/S market segment - Cancer blood
Kura Oncology is a biopharmaceutical company developing precision medicines for the treatment of blood cancers. Its valuation is based on the future potential of its drugs, which target specific genetic drivers of the disease. This chart, which reflects the average valuation in the sector, helps us understand how high investor expectations are for Kura's innovative approach.
P/S of the market as a whole
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. Its drugs target specific genetic mutations. This chart, which reflects market revenue estimates, highlights that Kura Oncology's value stems from investors' faith in the rigor of its scientific approach and its potential to transform patients' lives.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Kura Oncology Inc.
Kura Oncology is a biotech company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. Its value is determined by the potential of its scientific developments. This chart reflects investors' expectations that the company's candidates will successfully complete clinical trials and become new standards in oncology.
%20P%2FS%20Kura%20Oncology%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kura-Oncology-Inc.&v=1772650217710 "The graph of the company's future (projected) P/S Kura Oncology Inc.")
Future (projected) P/S of the market segment - Cancer blood
Kura Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of cancer, particularly blood cancers. This chart reflects average revenue expectations in the oncology sector. It allows investors to assess how highly the market values Kura Oncology's scientific potential.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772650217730 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. This chart reflects overall investor sentiment. Kura's success in clinical trials and its ability to bring new drugs to market contribute to the market's overall belief that scientific innovation can generate significant future value.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772650217731 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Kura Oncology Inc.
This chart illustrates the revenue of Kura Oncology, a clinical-stage biopharmaceutical company focused on developing targeted therapies for blood cancer. At this stage, its revenue, if any, comes from partnerships rather than sales. The trend reflects the progress of its research and the commercial potential of its developments.
Sales of companies in the market segment - Cancer blood
Kura Oncology is a biopharmaceutical company specializing in the development of precision drugs for the treatment of cancer, particularly hematologic malignancies. This chart illustrates the growth of the targeted oncology market. Kura's drugs target specific genetic drivers of cancer, and their success could offer new treatment options for patients with difficult-to-treat forms of the disease.
Overall market sales
Kura Oncology is a biopharmaceutical company focused on the treatment of blood cancer. Its growth depends on successful clinical trials and strategic partnerships. The overall economic situation, reflected in this chart, influences the level of investment in the biotech sector and the funding of advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Kura Oncology Inc.
Kura Oncology develops targeted therapies for the treatment of blood cancers and solid tumors. For a company in clinical development, this graph represents future revenue potential. It visualizes analyst expectations for the success of its research and drug commercialization.
%20sales%20of%20the%20company%20Kura%20Oncology%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kura-Oncology-Inc.&v=1772650217878 "Schedule of future (projected) sales of the company Kura Oncology Inc.")
Future (projected) sales of companies in the market segment - Cancer blood
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers such as leukemia. Its approach is based on a deep understanding of the genetic drivers of the disease. This chart shows the forecast for the entire oncology market, where Kura aims to offer new treatment options for patients with limited options.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772650217906 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers. Its success depends on the rigor of its scientific approach and the results of clinical trials. This chart illustrates the overall investment climate, but for Kura, demonstrating the efficacy of its drugs is key, which can attract investors even in a down market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772650217993 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Kura Oncology Inc.
Kura Oncology is a biotech company developing targeted drugs for the treatment of blood cancers and solid tumors. While in clinical trials, it incurs significant R&D expenses. This chart shows its net losses—investments in developing a new generation of targeted drugs that could offer hope to patients with difficult-to-treat cancers.
Market segment marginality - Cancer blood
Kura Oncology is a clinical-stage biopharmaceutical company developing targeted therapies for cancer, with a particular focus on hematological malignancies. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors analyze it to assess the potential of their innovative oncology drugs.
Market marginality as a whole
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. Their drugs target specific genetic mutations. This overall profitability curve is irrelevant to them. The company's value depends solely on the success of their clinical programs and the potential of their drugs in the oncology market.
Employees in the company, segment and market as a whole
Number of employees in the company Kura Oncology Inc.
Kura Oncology is a clinical-stage biotechnology company focused on the treatment of blood cancers. Its team consists of scientists and clinicians. The growth on this chart indicates the progress of its clinical programs and increased investment in the development of next-generation drugs.
Share of the company's employees Kura Oncology Inc. within the market segment - Cancer blood
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. This chart shows its share of the total number of researchers in this field. The growth in this figure reflects progress in clinical trials and the expansion of the scientific team working on creating personalized drugs for cancer patients.
Number of employees in the market segment - Cancer blood
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of blood cancers. This chart reflects employment trends in the highly specialized field of hematological oncology. The growing number of scientists and clinicians here signals progress in the development of targeted therapies for difficult-to-treat types of leukemia and lymphoma.
Number of employees in the market as a whole
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. Its approach is based on a deep understanding of cancer genetics. This chart demonstrates how the advances in personalized oncology driven by Kura are creating a demand for highly qualified scientists and clinical researchers.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Kura Oncology Inc. (KURA)
Kura Oncology is a biotech company specializing in precision medicine for cancer treatment. This chart reflects the market's valuation of its intellectual capital. The company's value is based on the potential of its drug candidates in clinical trials. The chart shows the high future value the market attributes to these developments, per scientist.
%20of%20the%20company%20Kura%20Oncology%20Inc.%20(KURA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kura-Oncology-Inc.-KURA&v=1772650218175 "Chart of market capitalization per employee (in thousands of dollars) of the company Kura Oncology Inc. (KURA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Kura Oncology is a biopharmaceutical company developing targeted therapies for blood cancer. Its valuation is based on the potential of its scientific developments. This chart demonstrates the high valuation of intellectual capital and future prospects based on its small team of scientists, which is typical for companies working at the forefront of oncology.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772650218178 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers and solid tumors. The chart reflects its scientific potential. The company's entire value is derived from the hope of successful clinical trials. This indicator demonstrates the value the market places on the work of each scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772650218179 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Kura Oncology Inc. (KURA)
Kura Oncology is a clinical-stage biotech company specializing in the development of targeted therapies for the treatment of blood cancers and solid tumors. This research-intensive R&D program is a testament to the high stakes involved: it shows the investment required for each scientist working on a potential breakthrough drug.
%20Chart%20Kura%20Oncology%20Inc.%20(KURA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kura-Oncology-Inc.-KURA&v=1772650218184 "Company Profit Per Employee (in thousands of dollars) Chart Kura Oncology Inc. (KURA)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Kura Oncology (KURA) is a clinical-stage biotechnology company developing targeted therapies for the treatment of blood cancer (leukemia). This metric (loss per employee) reflects the high cost of conducting complex clinical trials in oncology.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772650218216 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Kura Oncology is a clinical-stage biotech company specializing in targeted cancer therapy (including blood cancer). It is an R&D company and is not profitable. This chart shows the company's capital burn rate: the operating loss per research team leading the development of a new drug through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772650218226 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Kura Oncology Inc. (KURA)
Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers. This chart reflects the progress of its research commercialization. At this stage, the increase in revenue per employee is likely due to advance payments from major pharmaceutical partners.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kura-Oncology-Inc.-KURA&v=1772650218256 "Sales chart per company employee Kura Oncology Inc. (KURA)")
Sales per employee in the market segment - Cancer blood
Kura Oncology is a biotech company developing targeted drugs for the treatment of blood cancer (leukemia). This chart shows how productive their research team is. It measures revenue (from partnerships or early sales) per researcher, comparing them to other companies in the oncology sector.
Sales per employee for the market as a whole
Kura Oncology (KURA) is a biotech company focused on targeted therapies for the treatment of blood cancers and solid tumors. The company is in the clinical stage. This chart illustrates a typical biotech scenario: the company has no product revenue, and its entire staff of highly qualified scientists is dedicated to development and clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Kura Oncology Inc. (KURA)
Kura Oncology, Inc. is a biotech company specializing in targeted therapies for blood cancers. Its success depends on one or two key drug candidates. The bearish sentiment shown in this chart reflects investor bets that clinical trials for these drugs will fail or that their market potential is overestimated.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kura-Oncology-Inc.-KURA&v=1772650218317 "Short Shares Chart for the Company Kura Oncology Inc. (KURA)")
Shares shorted by market segment - Cancer blood
Kura Oncology is a biotech company developing targeted cancer therapies, primarily for hematological (blood) cancers. This indicator measures pessimism. "Shorts" here represent a bet that their key drugs (Ziftomenib, Tipifarnib) will fail in clinical trials.
Shares shorted by the overall market
Kura Oncology is a biotech company working on a treatment for blood cancer. The company is in clinical trials. When this chart shows rising fear, investors dump unprofitable stocks. For KURA, market pessimism is an existential threat, as raising new capital becomes extremely difficult.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Kura Oncology Inc. (KURA)
Kura Oncology (KURA) is a biotech company focused on precision oncology drugs, particularly for leukemia. Their success depends on R&D. This chart measures hype. It shows "overheated" (above 70) due to promising clinical trial data or "oversold" (below 30) due to news of delays or side effects of their candidates.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kura-Oncology-Inc.-KURA&v=1772650218508 "RSI 14 indicator chart for the company's stock Kura Oncology Inc. (KURA)")
RSI 14 Market Segment - Cancer blood
Kura Oncology (KURA) is a biotech company developing precision therapies for the treatment of blood cancer (leukemia). The RSI_14_Seg for "Cancer Blood" (biotech) shows the overall sentiment. The chart helps us understand: is KURA's volatility a reaction to its clinical trials, or is the entire biotech sector overheated (or oversold)?
RSI 14 for the overall market
Kura Oncology (KURA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KURA (Kura Oncology Inc.)
Kura Oncology (KURA) is a biotechnology company developing targeted therapies for the treatment of cancer, particularly acute leukemia and solid tumors. This chart represents analyst consensus. Their target prices are based on clinical data from their lead programs and an assessment of market potential in oncology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KURA-Kura-Oncology-Inc.&v=1772650218590 "A chart showing analyst consensus forecasts for the expected stock price. KURA (Kura Oncology Inc.)")
The difference between the consensus estimate and the actual stock price KURA (Kura Oncology Inc.)
Kura Oncology (KURA) is an oncology company developing targeted therapies (meningin inhibitors) for the treatment of acute leukemia. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their leading drug candidates for the treatment of blood cancers.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KURA-Kura-Oncology-Inc.&v=1772650218623 "A chart showing the difference between the consensus forecast and the actual stock price. KURA (Kura Oncology Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Kura Oncology (KURA) is a biotech company specializing in precision oncology. It develops targeted drugs for the treatment of blood cancer (leukemia). This chart shows overall expectations for the blood cancer sector. It reflects whether experts believe in the success of new "smart" leukemia drugs.
Analysts' consensus forecast for the overall market share price
Kura Oncology (KURA) is a clinical-stage biopharmaceutical company focused on cancer treatment. They develop smart drugs that target the signaling pathways that enable tumors to grow. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk treatments for blood cancer.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Kura Oncology Inc.
Kura Oncology is a biotech company focused on precision oncology. They develop smart drugs that target specific gene mutations that cause cancer (especially blood cancers). This graph represents pure R&D investment. It likely reflects the market's confidence in their scientific platform (targeting cancer drivers) and their early clinical data.
AKIMA Market Segment Index - Cancer blood
Kura Oncology (KURA) is a clinical-stage biotech focused on precision oncology (cancer); the company develops innovative targeted drugs (inhibitors for the treatment of blood cancers and solid tumors). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D focus (KURA) on cancer differentiate it from the average pharma company?
The AKIM Index for the overall market
Kura Oncology is a biotech company developing precision medicines for the treatment of blood cancers (leukemia) and solid tumors. Its key asset is Ziftomenib. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this high-potential clinical case stacks up against the backdrop of general economic trends affecting biotech.
